Northern Trust
TARS icon

Northern Trust’s Tarsus Pharmaceuticals TARS Stock Holding History

Northern Trust’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8M Buy
352,957
+10,471
+3% +$732K ﹤0.01% 1541
2025
Q4 		$28M Sell
342,486
-15,616
-4% -$1.17M ﹤0.01% 1451
2025
Q3 		$21.3M Buy
358,102
+924
+0.3% +$45.5K ﹤0.01% 1646
2025
Q2 		$14.5M Sell
357,178
-6,254
-2% -$281K ﹤0.01% 1848
2025
Q1 		$18.7M Buy
363,432
+5,816
+2% +$287K ﹤0.01% 1674
2024
Q4 		$19.8M Buy
357,616
+40,061
+13% +$1.82M ﹤0.01% 1692
2024
Q3 		$10.4M Buy
317,555
+64,539
+26% +$1.81M ﹤0.01% 2043
2024
Q2 		$6.88M Buy
253,016
+5,839
+2% +$196K ﹤0.01% 2219
2024
Q1 		$8.98M Sell
247,177
-1,573
-0.6% -$46.3K ﹤0.01% 2101
2023
Q4 		$5.04M Buy
248,750
+37,460
+18% +$626K ﹤0.01% 2506
2023
Q3 		$3.75M Buy
211,290
+18,007
+9% +$319K ﹤0.01% 2608
2023
Q2 		$3.49M Buy
193,283
+41,917
+28% +$666K ﹤0.01% 2699
2023
Q1 		$1.9M Sell
151,366
-3,149
-2% -$46.1K ﹤0.01% 2962
2022
Q4 		$2.27M Buy
154,515
+4,732
+3% +$78.3K ﹤0.01% 2941
2022
Q3 		$2.56M Buy
149,783
+10,636
+8% +$169K ﹤0.01% 2881
2022
Q2 		$2.03M Buy
139,147
+70,415
+102% +$1.06M ﹤0.01% 3058
2022
Q1 		$1.16M Sell
68,732
-3,049
-4% -$56.6K ﹤0.01% 3359
2021
Q4 		$1.61M Sell
71,781
-2,230
-3% -$58K ﹤0.01% 3327
2021
Q3 		$1.59M Sell
74,011
-5,624
-7% -$139K ﹤0.01% 3386
2021
Q2 		$2.31M Buy
79,635
+12,600
+19% +$394K ﹤0.01% 3286
2021
Q1 		$2.16M Sell
67,035
-3,364
-5% -$124K ﹤0.01% 3200
2020
Q4 		$2.91M Buy
+70,399
New +$2.01M ﹤0.01% 2987

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust's TARS Position: Q1 2026 in Review

Northern Trust increased its Tarsus Pharmaceuticals (TARS) stake by 3.1% in Q1 2026, buying an estimated $732K and bringing the position to 352,957 shares worth $24.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1541.

Northern Trust first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $28M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Northern Trust held 352,957 shares of Tarsus Pharmaceuticals worth $24.8M as of Q1 2026.
  • Northern Trust bought 10,471 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $732K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1541 holding.
  • Northern Trust first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Northern Trust's Tarsus Pharmaceuticals position peaked at $28M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.